AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is…
Roche has published early clinical data on its bispecific antibody in heavily pretreated patients with metastatic colorectal cancer.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
Shire's dominant position in the hereditary angioedema market just firmed up with stellar data for its new candidate lanadelumab.
President Donald Trump is considering switching up his attack on U.S. health research budgets by capping how much the NIH can spend on indirect costs.
Incyte is on the up after positive results for epacadostat—vying to be the first-in-class IDO1 inhibitor—alongside Merck's PD-1 blocker Keytruda.
Johnson & Johnson has listed the pipeline prospects it expects to drive the growth in its biopharma business for years to come.
AstraZeneca EVP Mene Pangalos has laid out how he wants the next government to support the United Kingdom’s life sciences sector through Brexit.
G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources…
AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract.
Editas Medicine has delayed the target date for filing an IND for its lead Allergan-partnered CRISPR program.